Hormonal
Semaglutide 2.4 mg significantly reduces major adverse cardiovascular events (MACE) in individuals with overweight or obesity without diabetes, establishing pharmacological weight loss as cardiovascular risk-modifying therapy.
If you have overweight or obesity but no diabetes, semaglutide 2.4 mg can help reduce your risk of serious heart problems like heart attack and stroke. This benefit is independent of your blood sugar levels. It is an injectable medication taken once a week. You should talk to your doctor about whether this is right for you, especially if you have other cardiovascular risk factors.
The SELECT trial demonstrated that semaglutide 2.4 mg significantly reduced major adverse cardiovascular events in individuals with overweight or obesity without diabetes, establishing—for the first time—that pharmacological weight loss can translate into hard cardiovascular outcome benefits independent of glycaemic control.
Why this rating
Based on a large cardiovascular outcome trial (SELECT).
Source
Modern pharmacotherapy of obesity: molecular mechanisms, clinical efficacy and future therapeutic directions
Navneeth Selvan · International Journal of Basic & Clinical Pharmacology · 2026
DOI 10.18203/2319-2003.ijbcp20260443
More from this paper
- Modern incretin-based and multi-agonist peptide therapies (GLP-1, GIP/GLP-1, and triple agonists) induce double-digit percentage weight loss (15-25%) that approaches or exceeds outcomes historically associated with bariatric surgery.Strong
- Classical anti-obesity agents (orlistat, phentermine-topiramate, naltrexone-bupropion) typically achieve only modest weight loss (3-10%) and are limited by tolerability and safety concerns.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →